CXCL13 and myeloid sarcoma: Interestingly, CXCL13 was reduced after treatment with methylprednisolone, used for controlling inflammation in MS relapses, and natalizumab, an inhibitor of leukocyte migration into the brain (Hutchinson, 2007).